Form 4: Director Michael Narachi Receives Ultragenyx Equity Award
Director Equity Grant
Director Michael Narachi was granted 7,751 restricted stock units and 14,058 stock options by Ultragenyx Pharmaceutical.
Summary
- Director Michael Narachi received an equity grant consisting of 7,751 Restricted Stock Units (RSUs) and 14,058 stock options.
- The stock options have an exercise price of $25.80 per share.
- Both the RSUs and the stock options are scheduled to vest in full on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.
Sentiment
Score: 5
Explanation: StockSavvy.ai views this as a routine administrative filing regarding director compensation, which is neutral in nature.
Positives
- Alignment of director interests with long-term shareholder value through equity-based compensation.
Negatives
- The issuance of new equity awards results in minor dilution to existing shareholders.
Risks
- Potential for future share price volatility affecting the value of the granted equity.
Future Outlook
The equity awards are subject to vesting conditions tied to the next Annual Meeting of Stockholders or May 14, 2027.
Management Comments
- No specific management commentary provided in this regulatory filing.
Industry Context
StockSavvy.ai notes that standard director compensation packages in the biotechnology sector frequently utilize a mix of RSUs and stock options to incentivize long-term oversight and strategic alignment.
Comparison to Industry Standards
- The grant structure is consistent with standard corporate governance practices for mid-cap pharmaceutical companies.
- Vesting periods of one year for director equity are common practice among peers in the life sciences industry.
Corporate Governance
| Change Type | Description | Effective Date | Impact Assessment |
|---|---|---|---|
| Equity Compensation | Grant of RSUs and stock options to Director Michael Narachi under the 2023 Incentive Plan. | 05/14/2026 | Standard alignment of director compensation with company performance. |
Stakeholder Impact
- Minor dilution for existing shareholders due to the issuance of new equity.
Next Steps
- Vesting of equity awards on the earlier of the next Annual Meeting of Stockholders or May 14, 2027.
Key Dates
| Date | Description |
|---|---|
| 05/14/2026 | Date of transaction and grant of equity awards. |
| 05/14/2027 | Vesting date for RSUs and stock options. |
| 05/14/2036 | Expiration date for the stock options. |
Keywords
Ultragenyx, RARE, Director Compensation, Equity Grant, Insider Transaction, Form 4
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.